Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Leerink Partners Global Biopharma Conference

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
February 06, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
December 06, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference

SEATTLE, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
November 09, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis

Preclinical data that supported initiation of the completed Phase 1a AP02 inhaled nintedanib study to be presented for the first time at the PFF Summit AP01 inhaled pirfenidone clinical data,...
November 06, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
October 05, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
September 29, 2023 06:30 ET | Source: Avalyn Pharma Inc.

Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference

SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
September 27, 2023 06:30 ET | Source: Avalyn Pharma Inc.

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation by new and current healthcare investors Funds to support Phase 2b development of AP01...
September 18, 2023 12:06 ET | Source: Avalyn Pharma Inc.

Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit

Seattle, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
September 12, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis

Seattle, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, and...